Loading news...
Quanterix (NASDAQ: QTRX - Get Free Report) and IM Cannabis (NASDAQ: IMCC - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk. Institutional and Insider Ownership 86.5% of Quanterix shares
TREES (OTCMKTS:CANN - Get Free Report) and Quanterix (NASDAQ: QTRX - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability. Profitability This table compares TREES and Quanterix's net margins,
Quanterix Corporation (QTRX) Q4 2025 Earnings Call Transcript
Quanterix Corporation (QTRX) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.3 per share a year ago.
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the fourth quarter and full year ended December 31, 2025. “I am thrilled to be joining Quanterix at a time when the company is well-positioned to deliver long-term growth,” said Everett Cunningham, President & CEO of Quanterix. “During the fourth quarter, we exceeded our revenue expectations, we con.
BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a partnership with Life Line Screening (LLS), a national organization focused on identifying asymptomatic risks for chronic conditions in community health settings. Through the partnership, Life Line Screening will offer Lucent's non-invasive blood based biomarker test nationally, with programs in Florida, California, and Texas already underway. This partnership supports the g.
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its executive leadership team will participate in the following investor conferences in March: 46th Annual TD Cowen Healthcare Conference Format: Fireside chat and one-on-one meetings Date: Wednesday, March 4, 2026 Time: 11:50 am ET Webcast: Click here Leerink Global Healthcare Conference 2026 Forma.
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that it will host a conference call on Monday, March 2, 2026, at 4:30 p.m. E.T., to discuss its fourth quarter and full year 2025 financial results. Quanterix will issue a press release regarding its fourth quarter and full year 2025 financial results prior to the conference call on Monday, March 2, 2026.
QTRX submits a 510(k) to the FDA for its multi-analyte blood test aimed at evaluating cognitive symptoms for possible Alzheimer's disease.
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for a multi-analyte algorithmic blood test for Alzheimer's disease (AD). This submission represents a significant milestone in the Company's mission to provide superior, non-invasive, high-performance diagnost.
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced publication of a landmark study in the high impact journal JAMA Network Open, https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2842215. The study, led by researchers at Amsterdam UMC, followed a cohort of nearly 300 individuals for up to 15 years. The findings demonstrated that while individu.
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on January 15, 2026, inducement grants (the “Inducement Grants”) were made to four employees in connection with the commencement of their employment. The Inducement Grants consist of 88,050 restricted stock units (“RSUs”) representing 88,050 shares of Quanterix common.
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the “Board”) has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Execu.
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced publication of a landmark study in the prestigious journal Nature. The study, which utilized Quanterix's ultra-sensitive Simoa p-Tau 217 (phosphorylated tau at threonine 217) research assay, is the largest population-based assessment of Alzheimer's Disease Neuropathological Changes (ADNC) to date, provid.
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board o.
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the publication of a landmark study in the high-impact journal Brain. The paper validates that multiplexed Simoa assays for Glial Fibrillary Acidic Protein (GFAP) and Neurofilament Light Chain (NfL) establish a robust, complementary two-pronged approach for comprehensive Multiple Sclerosis (MS) disease a.
Quanterix Corporation (NASDAQ: QTRX - Get Free Report) has earned a consensus rating of "Hold" from the five analysts that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and one has given a buy recommendation to the company. The average 1-year
Quanterix Corporation ( QTRX ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Joshua Young Masoud Toloue - President, CEO & Director Vandana Sriram - CFO & Treasurer Conference Call Participants Kyle Mikson - Canaccord Genuity Corp., Research Division Daniel Brennan - TD Cowen, Research Division Puneet Souda - Leerink Partners LLC, Research Division Tom DeBourcy - Nephron Research LLC Presentation Operator Hello, and thank you for standing by. My name is Tiffany, and I will be your conference operator today.
Quanterix Corporation (QTRX) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.22 per share a year ago.
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financial results for the third quarter ended September 30, 2025. “During the third quarter, we delivered on our revenue expectations despite challenging market conditions,” said Masoud Toloue, Chief Executive Officer of Quanterix. “Equally important, we achieved key integration milestones from our Akoya.